Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q26778298)
Watch
English
EGFR-TKIs in adjuvant treatment of lung cancer: to give or not to give?
scientific article
In more languages
edit
Statements
instance of
scholarly article
0 references
title
EGFR-TKIs in adjuvant treatment of lung cancer: to give or not to give?
(English)
0 references
author
Paul Zarogoulidis
series ordinal
14
object named as
Paul Zarogoulidis
0 references
Konstantinos Zarogoulidis
series ordinal
7
object named as
Konstantinos Zarogoulidis
0 references
Bojan Zaric
series ordinal
3
object named as
Bojan Zaric
0 references
author name string
Aleksandar Milovancev
series ordinal
1
0 references
Vladimir Stojsic
series ordinal
2
0 references
Tomi Kovacevic
series ordinal
4
0 references
Tatjana Sarcev
series ordinal
5
0 references
Branislav Perin
series ordinal
6
0 references
Katerina Tsirgogianni
series ordinal
8
0 references
Lutz Freitag
series ordinal
9
0 references
Kaid Darwiche
series ordinal
10
0 references
Drosos Tsavlis
series ordinal
11
0 references
Athanasios Zissimopoulos
series ordinal
12
0 references
Grigoris Stratakos
series ordinal
13
0 references
language of work or name
English
0 references
publication date
2015
0 references
published in
OncoTargets and Therapy
0 references
volume
8
0 references
page(s)
2915-21
0 references
copyright license
Creative Commons Attribution-NonCommercial 3.0 Unported
start time
1 October 2015
1 reference
stated in
April 2022 Public Data File from Crossref
copyright status
copyrighted
0 references
cites work
Global cancer statistics
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4610780
retrieved
7 April 2017
Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4610780
retrieved
7 April 2017
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4610780
retrieved
7 April 2017
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4610780
retrieved
7 April 2017
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4610780
retrieved
7 April 2017
Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4610780
retrieved
28 September 2017
Adjuvant chemotherapy and radiotherapy in the treatment of non-small cell lung cancer (NSCLC)
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4610780
retrieved
28 September 2017
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4610780
retrieved
28 September 2017
Adjuvant trastuzumab in HER2-positive breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4610780
retrieved
28 September 2017
Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4610780
retrieved
28 September 2017
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4610780
retrieved
28 September 2017
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4610780
retrieved
28 September 2017
The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4610780
retrieved
28 September 2017
A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4610780
retrieved
31 May 2018
Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4610780
retrieved
28 November 2018
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4610780
retrieved
28 November 2018
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4610780
retrieved
28 November 2018
Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/26508876
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.2147/OTT.S91627
0 references
PMC publication ID
4610780
0 references
PubMed publication ID
26508876
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit